G16C20/20

SYSTEM, METHOD, AND APPARATUS FOR PREDICTING PHYSICAL PROPERTIES BY INDIRECT MEASUREMENT

According to at least one exemplary embodiment, a system, method, and apparatus for predicting physical properties by indirect measurement is disclosed. The system, method, and apparatus provide for measurement of physical properties of petroleum products by calculating predictions of the properties based on diverse inputs. These predictions may be updated in real time and may be used to modify various processes in midstream and downstream petroleum operations. Various use cases for the system, method, and apparatus for predicting physical properties by indirect measurement are disclosed.

SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES

A sequencing method, system and kit of low molecular weight heparin (LMWH) oligosaccharides are provided. The sequencing method includes: a sample preparation step: isolating or preparing a group of LMWH oligosaccharide mixture samples; a sample treatment step: performing complete enzymatic digestion and nitrous acid degradation on the LMWH oligosaccharide mixture samples to obtain an enzymatically digested eight-common-heparin-disaccharide array, a 3-O-sulfate group array, a 1,6-anhydro structure array, a nitrous acid degradation array, respectively; a data processing step: obtaining a disaccharide isomeric unit array according to the enzymatically digested eight-common-heparin-disaccharide array and the nitrous acid degradation array; a sequence database building step: building a sequence database according to the degree of polymerization of the oligosaccharide mixture, the disaccharide isomeric unit array, the 3-O-sulfate group array, and the 1,6-anhydro structure array; and a specific result output step: screening the sequence database according to input qualification information and then outputting a specific result file.

SEQUENCING METHOD, SYSTEM AND KIT OF LOW MOLECULAR WEIGHT HEPARIN OLIGOSACCHARIDES

A sequencing method, system and kit of low molecular weight heparin (LMWH) oligosaccharides are provided. The sequencing method includes: a sample preparation step: isolating or preparing a group of LMWH oligosaccharide mixture samples; a sample treatment step: performing complete enzymatic digestion and nitrous acid degradation on the LMWH oligosaccharide mixture samples to obtain an enzymatically digested eight-common-heparin-disaccharide array, a 3-O-sulfate group array, a 1,6-anhydro structure array, a nitrous acid degradation array, respectively; a data processing step: obtaining a disaccharide isomeric unit array according to the enzymatically digested eight-common-heparin-disaccharide array and the nitrous acid degradation array; a sequence database building step: building a sequence database according to the degree of polymerization of the oligosaccharide mixture, the disaccharide isomeric unit array, the 3-O-sulfate group array, and the 1,6-anhydro structure array; and a specific result output step: screening the sequence database according to input qualification information and then outputting a specific result file.

COMPARING A MODELED MOLECULE FRAGMENTATION TO AN EXPERIMENTAL MOLECULE FRAGMENTATION
20220404371 · 2022-12-22 ·

Exemplary embodiments described herein provide improved techniques for matching an experimental mass spectrometry fragmentation against a known or predicted fragmentation from a library. Among other improvements, exemplary embodiments provide more accessible interfaces that are easier to interpret, thus allowing for more accurate and faster matches. They also may automatically accumulate multiple experimental results to determine whether several runs of a given sample cumulatively represent a library fragmentation pattern. Furthermore, exemplary embodiments provide simplified techniques for identifying and accounting for molecule variants.

COMPARING A MODELED MOLECULE FRAGMENTATION TO AN EXPERIMENTAL MOLECULE FRAGMENTATION
20220404371 · 2022-12-22 ·

Exemplary embodiments described herein provide improved techniques for matching an experimental mass spectrometry fragmentation against a known or predicted fragmentation from a library. Among other improvements, exemplary embodiments provide more accessible interfaces that are easier to interpret, thus allowing for more accurate and faster matches. They also may automatically accumulate multiple experimental results to determine whether several runs of a given sample cumulatively represent a library fragmentation pattern. Furthermore, exemplary embodiments provide simplified techniques for identifying and accounting for molecule variants.

Distinguishing protein aggregation mechanisms

Method, device, and system for identifying a model-based time dependent light scattering signature that includes receiving an experimental time dependent light scattering signature comprising experimental data descriptive of an average molecular weight of protein components in a solution over time. The method further includes identifying an Ansatz for evaluating the experimental time dependent light scattering signature, the Ansatz being an initial model-based time dependent light scattering signature, the initial model-based time dependent light scattering signature identifying at least one key variable. The method also includes adjusting the at least one key variable in the initial model-based time dependent light scattering signature until a final model-based time dependent light scattering signature is identified. In some instances, the final model-based time dependent light scattering signature identifies at least one protein aggregation mechanism.

Distinguishing protein aggregation mechanisms

Method, device, and system for identifying a model-based time dependent light scattering signature that includes receiving an experimental time dependent light scattering signature comprising experimental data descriptive of an average molecular weight of protein components in a solution over time. The method further includes identifying an Ansatz for evaluating the experimental time dependent light scattering signature, the Ansatz being an initial model-based time dependent light scattering signature, the initial model-based time dependent light scattering signature identifying at least one key variable. The method also includes adjusting the at least one key variable in the initial model-based time dependent light scattering signature until a final model-based time dependent light scattering signature is identified. In some instances, the final model-based time dependent light scattering signature identifies at least one protein aggregation mechanism.

Information processing apparatus, information processing method, and storage medium

According to one embodiment, an information processing apparatus comprises a processor. The processor is configured to receive a first number of outputs from the first number of sensors mutually different in response to an odor, obtain a second number of indicators by using the first number of outputs from the first number of sensors, the second number being larger than the first number, obtain the second number of indicator values by using the first number of outputs and the second number of indicators, and discriminate the odor based on the second number of indicator values.

Information processing apparatus, information processing method, and storage medium

According to one embodiment, an information processing apparatus comprises a processor. The processor is configured to receive a first number of outputs from the first number of sensors mutually different in response to an odor, obtain a second number of indicators by using the first number of outputs from the first number of sensors, the second number being larger than the first number, obtain the second number of indicator values by using the first number of outputs and the second number of indicators, and discriminate the odor based on the second number of indicator values.

Streamlined method for analytical validation of biochemicals detected using an untargeted mass-spectrometry platform
11527306 · 2022-12-13 · ·

A method of assessing the analytical performance of a biochemical measured using a multi-analyte assay is described. The method includes analytically validating a measurement of the level of a first biochemical in a sample, wherein the first biochemical has been previously analytically validated for three or more analytical validation conditions; measuring the level of a second biochemical in a sample, wherein the second biochemical is structurally or biochemically related to the first biochemical; and comparing validation parameters of the first biochemical with validation parameters of the second biochemical to determine whether the performance of the second biochemical is acceptable based on the comparison results.